Zevra Therapeutics Raises $72.3M, Still Can't Cure Investor Boredom at J.P. Morgan Conference

Zevra Therapeutics, a commercial-stage company with a unique opportunity to impact people living with rare diseases, presented at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, with CEO Neil McFarlane taking the stage to discuss their lead product, MIPLYFFA, which is being commercialized in the U.S. for Niemann-Pick disease type C. The company has an MAA under review by the EMA and is broadening access through geographic expansion opportunities, with a pipeline of rare disease programs and multiple revenue sources, generating $72.3 million in net revenue for the first 9 months of last year and exiting Q3 with a strong cash position of $230.4 million. With a growth mode mindset, Zevra is executing on its commercial and development priorities, but the real question is, can they cure the boredom of investors who have been listening to conference presentations all week? As the CEO took the stage, he thanked JPMorgan for the opportunity to present, acknowledging it's been a long week, and for those in the room, thanks for not falling asleep yet. The company's presentation was introduced by Susmita Roy, an associate on the JPMorgan Healthcare Investment Banking team, who highlighted Zevra's unique opportunity to impact people living with rare diseases.